Finding companies that have all the right stuff can produce winners. Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everything you could ...

Sanofi also said that it would increase the number of Phase 3 studies it is conducting by 50% between 2023 and 2025.

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want? One thing's for sure: You'll never discover ...

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want? One thing's for sure: You'll never discover ...

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want? One thing's for sure: You'll never discover ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, have ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.